GlassScriptPhysician profile
Vicki Cooper Baker
NPI 1669414876
$2,934.03
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $2,174 · 2021: $11.92 · 2024: $31.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $31.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $31.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,840.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $121.78 | 2019-2020 | |
| Astellas Pharma US INC | $117.88 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $92.24 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $86.86 | 2019-2020 | |
| Amgen INC. | $70.38 | 2019-2020 | |
| Genentech USA, INC. | $68.07 | 2019 | |
| Pfizer INC. | $64.70 | 2020 | |
| Tersera Therapeutics LLC | $51.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $38.57 | 2019-2020 | |
| Daiichi Sankyo INC. | $37.56 | 2020 | |
| Heron Therapeutics, INC. | $32.37 | 2019 | |
| Boston Scientific Corporation | $31.60 | 2024 | Watchman, Watchman Flx |
| Tesaro, INC. | $30.33 | 2019 | |
| Lilly USA, LLC | $27.90 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $27.07 | 2019 | |
| Gilead Sciences, INC. | $25.11 | 2019-2021 | |
| Taiho Oncology, INC. | $18.89 | 2019 | |
| Genzyme Corporation | $16.38 | 2019 | |
| Incyte Corporation | $16.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.50 | 2019 | |
| Emd Serono, INC. | $14.86 | 2019 | |
| Eisai INC. | $13.80 | 2019 | |
| Kyowa Kirin, INC. | $13.50 | 2019 | |
| Merck Sharp & Dohme LLC | $13.36 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.62 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $11.91 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $11.57 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicki Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.